Company intelligence / Profile preview

七星化學製藥

Tucheng District, New Taipei City, Taiwan

Ownership: Private
Employees: ~80
Development stage: Commercial

Overview

七星化學製藥 is a leading Taiwanese manufacturer of active pharmaceutical ingredients (APIs), with cGMP certifications from both the US FDA and Taiwan TFDA. The company exports nearly all its products globally and has a strong track record in regulatory compliance and quality manufacturing. It was acquired by Synmosa Biopharma Group in 2016 to strengthen vertical integration and expand into specialty APIs such as imaging agents and rare disease treatments[4][6].

Therapeutic areas: PulmonologyRare DiseasesNeurologyOther
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Drug pipeline

7 assets

carbocisteine

Commercial

6 more assets in the full pipeline.

Request access →

Partnerships

Akorn Inc. (for US distribution of MRI agents)[6]

Beyond the preview

Go deeper on 七星化學製藥.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 七星化學製藥.

Explore the full profile